SCHEDULE 13G/A: Blue Owl Capital Holdings Discloses 8.48% Passive Stake in Context Therapeutics Inc.

Blue Owl Capital Holdings LP has reported a passive beneficial ownership of 8.48% in Context Therapeutics Inc., holding 6,357,928 shares as of December 31, 2024.

Summary

• Blue Owl Capital Holdings LP filed an Amendment No. 1 to Schedule 13G, reporting its beneficial ownership in Context Therapeutics Inc.
• The Reporting Person, Blue Owl Capital Holdings LP, beneficially owns 6,357,928 shares of Context Therapeutics Inc. common stock.
• This ownership represents 8.48% of the outstanding common stock of Context Therapeutics Inc.
• The percentage is calculated based on 74,998,312 shares of common stock outstanding as of November 4, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed on November 6, 2025.
• Blue Owl Capital Holdings LP holds sole voting power and sole dispositive power over all 6,357,928 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. This is a standard regulatory filing (Schedule 13G) disclosing a passive beneficial ownership stake. It does not contain performance data or strategic updates that would typically influence sentiment positively or negatively, beyond the fact of a significant investment.

Positives

• Blue Owl Capital Holdings LP, a significant investment firm, has disclosed a substantial 8.48% passive stake in Context Therapeutics Inc., which may be viewed as a vote of confidence in the company.

Negatives

• No specific negative information regarding Context Therapeutics Inc. or its operations is disclosed in this beneficial ownership filing.

Risks

• This filing, a Schedule 13G, primarily reports beneficial ownership and does not detail specific risks associated with Context Therapeutics Inc.'s operations or financial health.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.

Management Comments

• Karen Hager, Chief Compliance Officer of Blue Owl Capital Holdings LP, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a standard regulatory disclosure of beneficial ownership and does not provide specific industry context or analysis.

Comparison to Industry Standards

• This beneficial ownership filing does not contain information suitable for comparison to industry-specific operational or financial benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• No litigation or regulatory matters are disclosed in this beneficial ownership filing.

Related Party Transactions

• No related party dealings are disclosed in this beneficial ownership filing.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive investment by Blue Owl Capital Holdings LP may be viewed positively, potentially signaling investor confidence in Context Therapeutics Inc.

Next Steps

• This filing is a regulatory disclosure of a passive ownership stake and does not outline specific future actions or milestones for Context Therapeutics Inc. or Blue Owl Capital Holdings LP.

Key Dates

Keywords

Context Therapeutics Inc., Blue Owl Capital Holdings LP, Schedule 13G, beneficial ownership, common stock, passive investment, equity stake